Abstracts Archive - Page 2160 of 2425 - ACR Meeting Abstracts

Abstract Number: 1372 • 2013 ACR/ARHP Annual Meeting
Do We Really Identify Latent Tuberculosis? Comparison Of The Performance Of Tuberculin Skin Test and Interferon Gamma Release Assay Before Biologics: A Systematic Review and Meta-Analysis
Marie Locci¹, Françoise Barchechath-Flaisler², Jean-Louis Leroux¹ and Cécile Gaujoux-Viala³, ¹Nîmes University Hospital, Rheumatology Department, Nîmes, France, ²Nîmes University Hospital, Rheumatology Department, Nimes, France, ³EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France
Background/Purpose: Current guidelines mandate screening for latent tuberculosis infection prior to commencing anti-tumor necrosis factor therapy. However, many patients are already taking immunosuppressive therapy, which…
Abstract Number: 1373 • 2013 ACR/ARHP Annual Meeting
Connective Tissue Growth Factor Promotes Angiogenesis Through Increased Notch-1 Signaling in Rheumatoid Arthritis
Kazuhisa Nozawa¹, Maki Fujishiro², Ayako Yamaguchi¹, Mikiko Kawasaki², Kazuhisa Iwabuchi², Mitsuaki Yanagida², Keigo Ikeda³, Shinji Morimoto⁴, Yoshinari Takasaki⁵ and Iwao Sekigawa³, ¹Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan, ³Internal Medicine 2, Juntendo University Urayasu Hospital, Tomioka, Urayasu, Chiba, Japan, ⁴Juntendo University Urayasu Hospital, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Juntendo University, Tokyo, Japan
Background/Purpose: Increased angiogenesis has been associated with various inflammatory disease states including rheumatoid arthritis (RA), and it has been considered as one of main factors…
Abstract Number: 1375 • 2013 ACR/ARHP Annual Meeting
Synergistic Enhancement Of Aggregated IgG-Induced Tumor Necrosis Factor α In Human Synovial Mast Cells By Interleukin 33
Hyunho Lee^1,2, Jun-ichi Kashiwakura³, Masahiko Yanagisawa^1,2, Yuki Okamura^1,2, Takao Ishii², Masayuki Seki², Shu Saito², Yasuaki Tokuhashi², Chisei Ra¹ and Yoshimichi Okayama¹, ¹Allergy and Immunology Group, Nihon University School of Medicine, Tokyo, Japan, ²Department of Orthopaedic Surgery, Nihon University School of Medicine, Tokyo, Japan, ³Laboratory for Allergic Disease, RIKEN Center for Integrateive Medical Sciences, Kanagawa, Japan
Background/Purpose: Recent studies suggest that human synovial mast cells (MCs) are involved in the pathogenesis of rheumatoid arthritis (RA). Circulating IgG isotype autoantibodies and synovial…
Abstract Number: 1376 • 2013 ACR/ARHP Annual Meeting
Low Vitamin D Level Is Not Associated With Increased Incidence Of Rheumatoid Arthritis
Jonida Cote¹, Androniki Bili¹, H. Lester Kirchner² and Xiaoqin Tang³, ¹Rheumatology, Geisinger Medical Center, Danville, PA, ²Geisinger Center for Health Research, Geisinger Health System, Danville, PA, ³Biostatistics, Geisinger Center for Health Research, Danville, PA
Background/Purpose: Vitamin D is thought to be an immunomodulator able to suppress autoimmunity in rheumatoid arthritis (RA). Some reports describe an association between low vitamin…
Abstract Number: 1346 • 2013 ACR/ARHP Annual Meeting
Drug Free Holiday In Patients With Rheumatoid Arthritis (RA): patients’ Opinion
I.M. Markusse, G. Akdemir, T.W.J. Huizinga and C.F. Allaart, Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Clinical trials have shown that in many patients tapering and/or stopping antirheumatic medication is a realistic option. We interviewed patients to investigate their opinions,…
Abstract Number: 1355 • 2013 ACR/ARHP Annual Meeting
Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of Methotrexate
Uwe Pichlmeier and Kay-Uwe Heuer, medac GmbH, Wedel, Germany
Background/Purpose: Methotrexate (MTX) is commonly used in the treatment of RA, psoriasis, and psoriatic arthritis. Subcutaneously administered MTX is well absorbed and appears to overcome…
Abstract Number: 1337 • 2013 ACR/ARHP Annual Meeting
Nearly Pain Free Self-Administration Of Methotrexate Using An Investigational Auto-Injector: Results Of a Phase-2 Clinical Trial In Rheumatoid Arthritis Patients With Mild-To-Severe Functional Limitations
Alan J. Kivitz¹, David McLain², John Hill³, Bruce Freundlich⁴, Jonathan Jaffe⁵ and Kaushik J. Dave⁶, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Rheumatology, McLain Medical Associates, PC, Birmingham, AL, ³Avail Clinical Research, DeLand, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Clinical Development, Antares Pharma Inc, Ewing, NJ, ⁶Product Development, Antares Pharma Inc, Ewing, NJ
Background/Purpose: Methotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment. Limitations of systemic exposure of oral MTX can affect its efficacy. Subcutaneous (SC) MTX…
Abstract Number: 1338 • 2013 ACR/ARHP Annual Meeting
Time To Institution Of Disease Modifying Anti-Rheumatic Drugs In Australian Patients With Early Rheumatoid Arthritis
Sharon Van Doornum¹, Joanne Tropea², Mark Tacey¹ and Danny Liew¹, ¹Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia, ²Melbourne EpiCentre, Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: Early introduction of disease-modifying anti-rheumatic drugs (DMARDs) has been shown to reduce joint destruction and long-term disability in rheumatoid arthritis (RA). Substantial and irreversible…
Abstract Number: 1339 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Of Biologics Agents For Patients With Rheumatoid Arthritis and Hepatitis B Carrier
Masahiro Tada¹, Tatsuya Koike², Akihiro Tamori³, Tadashi Okano¹, Yuko Sugioka¹, Kenji Mamoto¹, Kentaro Inui⁴ and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Hepatiology, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: Biologics suppress hepatitis B virus (HBV) replication and play an important role in eradicating HBV by stimulating HBV-specific cytotoxic T-cell responses. We found that…
Abstract Number: 1340 • 2013 ACR/ARHP Annual Meeting
Functional Disability and Quality Of Life Are More Likely Improved In Patients With Rheumatoid Arthritis Who Achieved The New ACR/EULAR Remission Criteria Compared To DAS28 Remission In Daily Practice
Yoko Shimizu¹, Ayako Nakajima², Eisuke Inoue³, Eiichi Tanaka⁴, Akiko Kobayashi³, Yohei Seto³, Shigeki Momohara³, Atsuo Taniguchi³ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The new ACR/EULAR remission criteria were proposed to predict favorable outcome in patients with rheumatoid arthritis (RA). To evaluate the functional disability and quality…
Abstract Number: 1341 • 2013 ACR/ARHP Annual Meeting
Significantly Less Glucocorticoids and Better Patient-Reported Outcomes In Women With Early Inflammatory Arthritis Using Oral Contraceptives Compared To Never Users
Gisela Westhoff¹, Rainer H. Straub², Frank Buttgereit³, Johanna Callhoff⁴ and Angela Zink⁵, ¹Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany, ²Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴German Rheumatism Research Center, Berlin, Germany, ⁵German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: Data on the effects of oral contraceptives (OC) on the course of inflammatory arthritis (IA) are controversial. However, a recent analysis of data from…
Abstract Number: 1342 • 2013 ACR/ARHP Annual Meeting
Prognosis In Espoir Rheumatoid Arthritis Cohort At 24 Months According To Remission Status At 12 Months: No Differences In Radiographic Scores According To Prior Remission Status, But Significant Differences In HAQ Scores, Highest For Boolean and RAPID3RJ1 Criteria
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Francis Guillemin⁴, Bruno Fautrel⁵ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Cochin Hospital, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵APHP, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Different criteria for remission in rheumatoid arthritis (RA) have been developed from a Core Data Set of 7 measures for the DAS28, SDAI, CDAI…
Abstract Number: 1343 • 2013 ACR/ARHP Annual Meeting
Are There Differences Between Young and Older Onset Early Rheumatoid Arthritis and Does This Impact Outcomes? An Analysis From The Canadian Early Arthritis Cohort
Michael Arnold¹, Vivian P. Bykerk², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, J. Carter Thorne⁶, Edward Keystone⁷ and Janet E. Pope⁸, ¹Medicine/Rheumatology, University College Dublin, Ireland, Dublin, Ireland, ²Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁵Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ⁸Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
Background/Purpose: To determine the impact of age on disease and remission in early rheumatoid arthritis (ERA). Methods: Data from the Canadian Early Arthritis Cohort (CATCH)…
Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Eiichi Tanaka¹, Eisuke Inoue², Yoko Shimizu³, Akiko Kobayashi², Naoki Sugimoto², Daisuke Hoshi², Kumi Shidara², Eri Sato³, Yohei Seto², Ayako Nakajima⁴, Shigeki Momohara², Atsuo Taniguchi² and Hisashi Yamanaka³, ¹Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…
Abstract Number: 1345 • 2013 ACR/ARHP Annual Meeting
Retinal Vascular Calibre – a Novel Biomarker Of Inflammation and Treatment Response In Rheumatoid Arthritis
John HY Moi^1,2, Lauren AB Hodgson^3,4,5, Ian P Wicks^1,6,7, Tien Yin Wong^3,4,5,8 and Sharon Van Doornum^1,3,9, ¹Department of Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ²Department of Medicine, The University of Melbourne, Melbourne, Australia, ³The University of Melbourne, Melbourne, Australia, ⁴Royal Victorian Eye and Ear Hospital, Melbourne, Australia, ⁵Centre for Eye Research Australia, Melbourne, Australia, ⁶Department of Medical Biology, University of Melbourne, Parkville, Australia, ⁷Inflammation Division, Walter & Eliza Hall Institute of Medical Research, Parkville, Australia, ⁸Singapore Eye Research Institute, Singapore, Singapore, ⁹Melbourne EpiCentre, The Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: Retinal vascular calibre measurement is a non-invasive tool for assessing systemic and vascular health. Widened retinal venular calibre (RVC) is associated with systemic inflammation,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].